Logo
x

Search category

Subscribe Now

Teva

Insights+: The US FDA New Drug Approvals in May 2023

Insights+: The US FDA New Drug Approvals in May 2023

  • June 22, 2023
Teva and MedinCell Receive the US FDA’s Approval of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia

Teva and MedinCell Receive the US FDA’s Approval of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia

  • May 1, 2023
Teva's Partner Alvotech Receives Complete Response Letter on the BLA of AVT02 (biosimilar, adalimumab)

Teva's Partner Alvotech Receives Complete Response Letter on the BLA of AVT02 (biosimilar, adalimumab)

  • April 14, 2023
Teva’s Austedo XR (deutetrabenazine) Extended-Release Tablets Receives the US FDA’s Approval for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease

Teva’s Austedo XR (deutetrabenazine) Extended-Release Tablets Receives the US FDA’s Approval for Tardive Dyskinesia and Chorea Ass...

  • February 17, 2023
Teva Reports 3-Year (ARC-HD) Study Results of Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease

Teva Reports 3-Year (ARC-HD) Study Results of Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s...

  • October 19, 2022
Teva’s Ranivisio (biosimilar, ranibizumab) Receives EC’s Approval for Retinal Diseases

Teva’s Ranivisio (biosimilar, ranibizumab) Receives EC’s Approval for Retinal Diseases

  • August 29, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.